About

Jon Odorico is a researcher affiliated with the Department of Surgery at the University of Wisconsin School of Medicine and Public Health. The provided page text does not include specific details about his research focus, background, or key contributions. Therefore, no detailed biography can be extracted from the available content.

Research topics

• Medicine
• Endocrinology
• Internal medicine
• Political Science
• Intensive care medicine
• Surgery
• Law
• Urology
• General surgery
• Gastroenterology
• Cell biology
• Biology

Selected publications

• Banff 2024 Pancreas Transplantation Report: Diagnosis and impact of chronic active T cell-mediated allograft rejection and re-evaluation of the indeterminate category with utilization of leukocyte immunostains in biopsies with ambiguous findings

  American Journal of Transplantation · 2026-04-01

  articleOpen access

  The current Banff report summarizes topics central to the pancreas session in the 2024 conference held in Paris (France). The focus of discussion was on diagnostic criteria of chronic active rejection, the indeterminate (IND) category, and the utility of immunostains in pancreas transplant biopsies. Concepts were validated in a retrospective PanTxBx cohort after the meeting. First, chronic active rejection criteria introduced in the 2022 report were confirmed, and recommendations were refined. The clinical relevance of this category, with an increased risk of graft loss, was proven in the retrospective cohort. Second, the so far very narrowly defined IND category was expanded from septal inflammation to also include subthreshold lobular changes and incomplete findings of antibody-mediated rejection. IND cases were evaluated in the context of the clinical findings and CD3 and CD68 immunostaining. This process helped in further subcategorizing the IND diagnoses into rejection and non-rejection events and, third, led to the general recommendations provided for utilization of CD3 and CD68 immunostains to facilitate the histologic diagnosis in unclear biopsies. The working group expects that the current recommendations and refinements will enhance the applicability and reproducibility of the histopathological pancreas schema. Additionally, an outlook is given regarding ongoing projects and future perspectives.

  PublisherDOI

• Extracellular Matrix—Key to Maintaining Function of Encapsulated Human Stem Cell Differentiated Islet Clusters Seeded into Scaffolds as a Diabetes Therapy

  Diabetology · 2026-01-01

  articleOpen access

  Background/Objectives: A stem cell therapy for type 1 diabetes (T1D) is experimentally available but only to those few humans in whom the use of systemic immunosuppression can be justified. For others with T1D, a means to deliver the islets needs to be perfected. We have previously bioengineered a removable device for this purpose and now wish to test the effect of adding extracellular matrix (ECM) derived from decellularised human pancreas to it. Methods: The complete device consists of encapsulated pluripotent stem cell differentiated islets seeded into tubular scaffolds of polycaprolactone made by melt electrospin writing and to which ECM was added. The seeded device was implanted either subcutaneously (SC) or intraperitoneally (IP) into streptozotocin diabetic immunodeficient mice. The outcome over the next few months was compared with that achieved in diabetic mice implanted IP with encapsulated islets alone. Results: The device seeded with encapsulated islets but not containing ECM functioned less well than encapsulated islets implanted alone, with lower human C-peptide production. However, when ECM was added to the seeded device and whether implanted SC or IP, islets functioned as efficiently as those implanted without use of a scaffold. Conclusions: These data provide optimism for the use of seeded scaffolds in diabetic humans in whom a single scaffold seeded with multiple encapsulated islets can more readily be removed if needed for safety reasons than can multiple encapsulated islets not seeded into a scaffold.

  PublisherDOI

• Dual Kidney Transplantation Offers Prolonged Graft Survival

  Clinical Transplantation · 2026-02-01

  articleOpen access

  INTRODUCTION: Dual kidney transplantation (DKT), an uncommonly performed procedure, provides a unique opportunity to transplant nonstandard kidneys that might otherwise not be utilized. We compared perioperative and five-year posttransplant outcomes between DKT, and single kidney transplants (SKT) performed at our institution. METHODS: We analyzed all adult deceased donor kidney-alone transplant recipients at our center between 2001 and 2020. Recipients of pediatric en bloc kidney transplants were excluded. Perioperative outcomes of interest included delayed graft function (DGF), posttransplant length of stay (LOS), rehospitalization, and reoperation. Five-year outcomes included biopsy-proven acute rejection (AR), death-censored graft failure (DCGF), uncensored graft failure (UCGF), and death with functioning graft (DWFG). RESULTS: A total of 100 DKT and 3125 SKT recipients were included. DKT recipients were older (p < 0.001), more often male (68%), and more often underwent early steroid withdrawal (p = 0.04). In comparison to SKT, after adjustment for multiple variables, DKT was not independently associated with DGF (aOR: 1.25; 95% CI 0.76-2.08); prolonged LOS (linear coefficient 0.42; -0.9-1.7); reoperation (aOR: 0.73; 95% CI: 0.21-2.51) or rehospitalization (aOR 0.98; 95% CI: 0.55-1.74). However, within five years, DKT had a lower adjusted incidence rate ratio (aIRR) for AR (aIRR: 0.28; CI 0.12-0.64); DCGF (aIRR: 0.30; 95% CI 0.13-0.68), and UCGF (aIRR: 0.53; 95% CI: 0.33-0.86), without statistically significant differences in DWFG (aIRR: 0.83; 95% CI: 0.46-1.53). CONCLUSION: In selected recipients, DKT offered superior medium-term outcomes compared to SKT without compromising perioperative outcomes. DKT can mitigate concerns associated with medically complex donor kidneys, increase organ utilization, and increase access to transplantation.

  PublisherOA PDFDOI

• Donor-Derived Cell-Free DNA in Pancreas-Kidney, Heart-Kidney, and Liver-Kidney Multiorgan Transplant Recipients (MOTR)

  Transplant International · 2026-01-19

  articleOpen access

  Donor-derived cell free DNA (dd-cfDNA) is an established biomarker for detection of rejection in single organ transplants; data is limited in multi-organ transplant (MOT) recipients. "Use of dd-cfDNA in Multi-Organ Transplant Recipients" (MOTR) was a multicenter, prospective, cross-sectional study that assessed dd-cfDNA fraction (%) and donor quantity score (DQS, cp/mL) in pancreas-kidney (PKT), heart-kidney (HKT), and liver-kidney (LKT) recipients. We explored dd-cfDNA baseline levels across the different organ combinations, and compared them to kidney-only (KT) and heart-only (HT) transplant recipients. Among 347 MOT recipients from 18 sites (PKT = 183, HKT = 57, LKT = 107), most (88.2%) had simultaneous transplants. Median dd-cfDNA levels in PKT and HKT recipients were not significantly different from KT; median dd-cfDNA levels among HKT recipients were significantly higher than in HT recipients (p < 0.001). In LKT recipients, median dd-cfDNA was significantly higher compared to KT (p < 0.001). dd-cfDNA showed associations with organ impairment indicated by abnormal values of pancreatic and liver enzymes in PKT and LKT. As the largest multi-center study to date evaluating dd-cfDNA levels in MOT recipients, MOTR showed that organ-specific physiology affects dd-cfDNA levels across organ transplant combinations, laying the foundation for future efforts to use dd-cfDNA to assess organ-specific signatures of allograft injury in MOT recipients.

  PublisherOA PDFDOI

• Predicted Indirectly Recognizable T-cell Epitope (PIRCHE) Load Correlates With Rejection Events After Simultaneous Pancreas-Kidney Transplantation

  Transplantation Direct · 2025-02-07 · 1 citations

  articleOpen access

  Background: Given the lack of specificity of current blood and urine testing and the resistance/inability to perform pancreas allograft biopsies, additional noninvasive investigational tools to assess the risk for rejection are needed. This study examines the clinical impact of molecular HLA matching in a large single-center simultaneous pancreas-kidney (SPK) transplant program. Methods: The study cohort comprised 238 SPK recipients between 2012 and 2021. The number of HLA mismatches, eplet, Snow (that counts the number of protein-specific surface-accessible donor HLA amino acid mismatches), and predicted indirectly recognizable T-cell epitope (PIRCHE, version 4.2; 100%) loads were calculated on the basis of 2-field HLA-A, -B, -C, -DRB1, and -DQB1 typing of recipients and donors. Univariable and multivariable Cox proportional hazard, as well as Kaplan-Meier analyses, were performed considering either first rejection events of a graft or a composite endpoint of de novo donor-specific antibodies, first rejection, and uncensored graft failure of either organ. Results: Kaplan-Meier analyses considered class II PIRCHE groups separated by a threshold of 7. From the considered histocompatibility metrics, multivariable regression analysis revealed only PIRCHE-II derived from donor HLA class II as statistically significantly correlated with clinical events and rejection after SPK, mostly driven by pancreas rejections. Furthermore, longer dialysis time and the induction agent had significant negative impacts on the defined composite endpoint. Conclusions: Our data support the clinical benefit of incorporating PIRCHE scores for the interpretation of class II HLA mismatches among patients undergoing SPK transplantation.

  PublisherDOI

• The Challenge of Minding the Glomerular Filtration Rate Gap Between Pancreas Transplant Alone and Simultaneous Pancreas-Kidney Transplantation: Stuck in the Middle

  Transplantation · 2025-03-25

  articleSenior author
  PublisherDOI

• Positive Malnutrition Risk Factors Pre-Transplant Are Associated with Adverse Outcomes After Simultaneous Kidney and Pancreas and Solitary Pancreas Transplantation

  American Journal of Transplantation · 2025-08-01 · 1 citations

  article
  PublisherDOI

• A Multicenter Study of Weight Loss and Side Effects in Pancreas Transplant Recipients Treated with GLP-1 Receptor Agonists

  American Journal of Transplantation · 2025-08-01

  articleOpen access
  PublisherOA PDFDOI

• 140-OR: Durable Glycemic Control and Elimination of Exogenous Insulin Use with VX-880 in Patients with Type 1 Diabetes (T1D)—VX-880-101 (FORWARD)

  Diabetes · 2025-06-20 · 2 citations

  article

  Introduction and Objective: VX-880 is an allogeneic stem cell-derived, fully differentiated islet cell therapy in clinical development for T1D. Methods: This single-arm, open-label, phase 1/2/3 trial is evaluating VX-880 in T1D adults with impaired hypoglycemia awareness and ≥2 severe hypoglycemic episodes (SHEs) the year before enrollment. Participants receive a standard immunosuppression regimen. Enrollment and dosing in the phase 1/2 portion has completed and phase 3 is ongoing. Results: These results reflect 12 participants who received a full VX-880 dose as a single infusion and were followed for at least one year, as of October 2024. At baseline, all participants had multiple SHEs and undetectable fasting C-peptide. All 12 participants demonstrated engraftment with glucose responsive C-peptide production at Day (D)90 MMTT which was durable through Month (M)12. All 12 participants achieved ADA HbA1c target of &amp;lt;7% (mean: baseline=7.8%; M12=6.0%) and time in range target of &amp;gt;70% (mean: baseline=49.5%; M12=93%); and all were free of SHEs from D90 onwards. All 12 participants had reduction in exogenous insulin use (mean reduction: 92%) and 10/12 (83%) no longer required exogenous insulin at M12. Median duration free of exogenous insulin was 232 (69 to 441) days. All 12 participants were evaluable for and achieved the phase 1/2 primary endpoint of elimination of SHEs and HbA1c &amp;lt;7%. Most adverse events (AEs) were mild or moderate in severity. There were no VX-880-related serious AEs. Two deaths occurred; both were reported previously and unrelated to VX-880. Overall, the safety profile was consistent with the immunosuppressive regimen and islet infusion procedure. Conclusion: These durable clinical benefits of VX-880 with elimination of SHEs, improved glycemic control, and freedom from exogenous insulin support the curative potential of VX-880, the first and only allogeneic, stem-cell derived, islet cell therapy in pivotal development. Disclosure M.R. Rickels: Consultant; Vertex Pharmaceuticals Incorporated, Sernova, Corp. Research Support; Dompé, Tandem Diabetes Care, Inc. Consultant; Novo Nordisk. P. Witkowski: Advisory Panel; Vertex Pharmaceuticals Incorporated. Research Support; Sernova, Corp. Stock/Shareholder; Eledon. T.W. Reichman: Research Support; Vertex Pharmaceuticals Incorporated. Advisory Panel; Novo Nordisk. E.J. de Koning: None. J.F. Markmann: Consultant; iTolerance, Inc, Vertex Pharmaceuticals Incorporated. J.S. Odorico: Other Relationship; Regenerative Medical Solutions, Inc. Research Support; Juvenile Diabetes Research Foundation (JDRF). Other Relationship; Vertex Pharmaceuticals Incorporated, Veloxis. Research Support; National Institute of Diabetes and Digestive and Kidney Diseases. Consultant; UpToDate, Sernova, Corp. M. Wijkstrom: Consultant; Vertex Pharmaceuticals Incorporated. L.S. Kean: Consultant; Vertex Pharmaceuticals Incorporated. Research Support; Bristol-Myers Squibb Company, Tessera, Gilead Sciences, Inc, Novartis Pharmaceuticals Corporation. Advisory Panel; HiFi Bio. Research Support; Tonix, Merck &amp; Co., Inc. C. Mathieu: Advisory Panel; Novo Nordisk, Sanofi, Eli Lilly and Company, Abbott, Medtronic, SAB Biotherapeutics, Inc, Roche Diabetes Care, Vertex Pharmaceuticals Incorporated, Biomea Fusion, Bayer Pharmaceuticals, Inc. A.L. Peters: Advisory Panel; Medscape. Consultant; Vertex Pharmaceuticals Incorporated. Research Support; Insulet Corporation, Abbott. Other Relationship; Omada Health. Y. Tan: None. K. Vanijcharoenkarn: None. D. Melton: Employee; Vertex Pharmaceuticals Incorporated. Stock/Shareholder; Sana Biotechnology. F. Pagliuca: Employee; Vertex Pharmaceuticals Incorporated. B. Bruinsma: Employee; Vertex Pharmaceuticals Incorporated. G. Marigowda: Employee; Vertex Pharmaceuticals Incorporated. C. Ricordi: Advisory Panel; Vertex Pharmaceuticals Incorporated, Novo Nordisk.

  PublisherDOI

• Outcomes and Predictors of Pancreas Graft Survival in Simultaneous Pancreas-Kidney Transplant Recipients: A Contemporary Analysis of OPTN Database

  American Journal of Transplantation · 2025-08-01

  articleOpen access
  PublisherOA PDFDOI

Recent grants

• NIH Grant R21DK078889

  NIH · $404k · 2011

• Transformational platform for regenerating autologous transplantable endocrine tissue from human pancreatic matrix and pluripotent stem cells

  NIH · $408k · 2016–2019

Frequent coauthors

• Hans W. Sollinger

  University of Wisconsin–Madison

  114 shared

• Dixon B. Kaufman

  86 shared

• Stuart J. Knechtle

  Duke University

  70 shared

• Didier A. Mandelbrot

  University of Wisconsin Health

  61 shared

• Yolanda T. Becker

  University of Chicago

  60 shared

• Sandesh Parajuli

  58 shared

• James F. Markmann

  Massachusetts General Hospital

  55 shared

• Glen Leverson

  University of Wisconsin–Madison

  54 shared

Labs

• Dr. Odorico's LabPI

Awards & honors

• Best Doctors in America Award Surgery, Transplantation
• Madison Magazine Top Docs 2012 Award Surgery, Transplantatio…
• Avant-Garde Health General Surgery Research All-Stars (2024)